Inventiva SACA

Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D

18 3 2024 16:00:00 提供 Nasdaq GlobeNewswire

Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D

13 3 2024 16:00:00 提供 Nasdaq GlobeNewswire

Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed

07 3 2024 16:00:00 提供 Nasdaq GlobeNewswire

Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3

15 2 2024 16:35:00 提供 Nasdaq GlobeNewswire

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

24 1 2024 16:15:00 提供 Nasdaq GlobeNewswire

Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank

10 1 2024 16:00:00 提供 Nasdaq GlobeNewswire

Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program

20 12 2023 16:00:00 提供 Nasdaq GlobeNewswire

Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH

04 12 2023 16:05:00 提供 Nasdaq GlobeNewswire

Inventiva reports 2023 Third Quarter Financial Information¹

21 11 2023 16:00:00 提供 Nasdaq GlobeNewswire

Inventiva announces a late breaker abstract and two additional abstracts on its lead compound, lanifibranor, at the AASLD The Liver Meeting® 2023  

06 11 2023 16:00:00 提供 Nasdaq GlobeNewswire

Inventiva reports its 2023 first-half financial results and provides a corporate update

28 9 2023 16:00:00 提供 Nasdaq GlobeNewswire

Inventiva and Hepalys Pharma, Inc. announce exclusive licensing agreement to develop and commercialize lanifibranor in Japan and South Korea

20 9 2023 16:00:00 提供 Nasdaq GlobeNewswire

Inventiva announces a financing of approximately €35.7 million from new and existing investors, consisting of a €30.6 million reserved capital increase and a €5.1 million issuance of royalty certificates

31 8 2023 01:30:00 提供 Nasdaq GlobeNewswire

Correction: Inventiva Reports Preliminary 2023 First-Half Financial Information¹ and Business update

27 7 2023 16:00:00 提供 Nasdaq GlobeNewswire

Inventiva announces the presentation of a scientific abstract at the 83rd Scientific Sessions of the American Diabetes Association

24 6 2023 02:00:00 提供 Nasdaq GlobeNewswire

Inventiva announces positive topline results from the investigator-initiated Phase II clinical trial evaluating lanifibranor in patients with T2D and NAFLD

13 6 2023 17:00:00 提供 Nasdaq GlobeNewswire

Inventiva and Echosens launch joint initiative to increase NASH awareness and access to screening for at-risk patients  

08 6 2023 02:30:00 提供 Nasdaq GlobeNewswire

Inventiva announces five scientific presentations at the EASL International Liver Congress™ 2023

07 6 2023 16:00:00 提供 Nasdaq GlobeNewswire

Results of the votes of the Combined Shareholders’ General Meeting of May 25, 2023

26 5 2023 16:00:00 提供 Nasdaq GlobeNewswire

Inventiva announces that its partner Sino Biopharm received IND approval from the NMPA to initiate clinical trial with lanifibranor in China

25 5 2023 16:00:00 提供 Nasdaq GlobeNewswire